Supplement marketer Natrol enters sports fitness market with acquisition of Prolab Nutrition, a seller of sports nutrition products for bodybuilders through gyms, health food stores and other outlets. Natrol is paying $29 mil. cash and 124,270 shares of common stock for the company. Bloomfield, Conn.-based Prolab is expected to post over $30 mil. in sales for 1999. Chatsworth, Calif.-based Natrol plans to assist Prolab with manufacturing, purchasing and product/sales channel development, while Prolab will help enhance Natrol's international sales with its leading market position in Canada and presence in the U.K. and Germany, the firms say. Prolab is expanding its 32,000 sq. ft. distribution facility by 20,000 sq. ft. in the coming months
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
If approved, Sanofi’s acoziborole could become the first single-dose oral treatment for sleeping sickness.
Mexico’s drugs regulator will be able to grant quicker drug approvals based on decisions issued by World Health Organization listed authorities and founding ICH members.
Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.
